Guard Therapeutics Q4: Exciting Times Ahead
Redeye notes that the Q4 report from Guard did not include any surprises. We provide a brief comment on the financials and highlight the most important events during the period. We continue to see a good case in Guard and reiterate our Base case of SEK 3 per share.